• TTI-622 (SIRPa-IgG4 Fc) com­pleted 8 mg/kg safety assess­ment in the on­go­ing dose escalation study in re­lapsed / re­frac­tory lym­phoma; now es­ca­lat­ing to 12 mg/kg dose level.
• TTI-622 mono­therapy shows 6/18 (33%) objective re­sponses at 0.8 to 8 mg/kg dose levels, in­clud­ing 3/6 (50%) objective re­sponses at 8 mg/kg.
• TTI-621 (SIRPa-IgG1 Fc) well tol­er­ated at 1.4 mg/kg; con­tinues to show mono­therapy signal and dose-depen­dent im­prove­ment in skin dis­ease scores in the on­go­ing dose escalation study in re­lapsed / re­frac­tory CTCL.
• Trillium to host conference call at 5:30 p.m. ET to­day

Cambridge, MA (Press Release) – Trillium Thera­peutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clin­i­cal stage immuno-oncology com­pany devel­op­ing inno­va­tive ther­a­pies for the treat­ment of can­cer, to­day an­nounced up­dated data from its on­go­ing TTI-622 and TTI-621 dose escalation stud­ies.

“We are exceedingly en­cour­aged by the evolving profile of TTI-622, our SIRPa-IgG4 Fc fusion pro­tein, as dem­onstrated in the on­go­ing dose escalation study in re­lapsed and re­frac­tory lym­phomas,” said Jan Skvarka, Trillium’s Pres­i­dent and Chief Exec­u­tive Of­fi­cer. “TTI-622 is showing sub­stan­tial …